September 30, 2022


U.S. Securities and Exchange Commission

Division of Corporation Finance

Office of Life Sciences

100 F Street, N.E.

Washington, DC 20549-3720

Attention:        Dillon Hagius



Ventyx Biosciences, Inc. (the “Registrant”)

Registration Statement on Form S-1 (File No. 333-267626)

Request for Acceleration

Acceleration Request

Requested Date: October 4, 2022

Requested Time: 4:00 PM ET

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ventyx Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-267626) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Martin Waters at (858) 350-2308.

The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statements.

[Signature page follows]


Securities and Exchange Commission

September 30, 2022

Page 2


/s/ Raju Mohan
Raju Mohan
Chief Executive Officer



Christopher Krueger, Ventyx Biosciences, Inc.

Martin Auster, Ventyx Biosciences, Inc.

Martin J. Waters, Wilson Sonsini Goodrich & Rosati, P.C.

Robert L Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C.